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Abstract: It is widely predicted that cost and efficiency gains in sequencing will usher in an era of personal genomics and 
personalized, predictive, preventive, and participatory medicine within a decade. I review the computational challenges 
ahead and propose general and specific directions for research and development. There is an urgent need to develop se-
mantic ontologies that span genomics, molecular systems biology, and medical data. Although the development of such 
ontologies would be costly and difficult, the benefits will far outweigh the costs. I argue that availability of such ontolo-
gies would allow a revolution in web-services for personal genomics and medicine. 
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INTRODUCTION 
  The cost per nucleotide of DNA sequencing has been 
dropping exponentially for more than a decade [1]. In 2005, 
the National Human Genome Research Institute (NHGRI) 
awarded a series of research grants to develop technologies 
capable of sequencing an entire human genome for $1000. 
Currently, there are at least nine commercial ventures racing 
towards this goal [1].  
  While the availability of cheap, diploid, full-genome se-
quences may still be several years away, low-cost tests for 
large numbers of SNPs and other sequence variations are 
already being used by companies such as 23andMe (https:// 
www.23andme.com/), NaviGenetics (http://www.navigenics. 
com/) and deCODE Genetics (http://www.decode.com/) to 
provide personal disease-susceptibility profiles. Other com-
panies, such as KNOME (http://www.knome.com/) are of-
fering full personal genome sequencing for those who can 
afford the current costs.  
  Thus, DNA sequence variability data is becoming in-
creasingly available to individuals. The extent to which the 
availability of such data will lead to improvements in health- 
care depends on four criteria, as set out by the US Centers 
for Disease Control (http://www.cdc.gov/genomics/gtesting/ 
ACCE.htm): 
1. Accuracy of genotyping. The frequency of incorrect 
calls must be very low indeed before personal genetic 
profiles can be commercially viable. The accuracy will 
depend on the sequencing technology. Due to factors 
such as fold-coverage, it will to some extent be deter-
mined by economic considerations.  
2.  Predictive value of genotypes. Assuming a list of cor-
rectly identified genetic polymorphisms in an individual, 
the extent to which we can predict phenotypic outcomes 
will vary according to how much is known about the 
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  identified polymorphisms, the extent to which environ-
mental and life-history factors can influence the pheno-
types, etc.  
3.  Clinical utility of knowing genotypes. Even given an 
accurate genotype and a high-confidence prediction of a 
phenotype, we may not be able to predict the rate of dete-
rioration, or the risk of unacceptable adverse-effects for 
some treatments, or a treatment may simply not be avail-
able. For these and many other reasons, it is not always 
useful to know disease-associated genotypes.  
4. Ethical, legal and social issues arising. Considerable 
concerns have been raised over the lack of standards for 
genetic test, information security, potential social stigma/ 
discrimination, and provision of impartial advice to ‘pa-
tients’ (see for example [2]). Though government regula-
tions such as the US Genetic Information Non Discrimi-
nation Act [3] have been discussed for over a decade, 
public awareness and debate on these issues is still lim-
ited to specialist communities. 
  In this paper, I will assume that genotype data made 
available to individuals will be very high quality, and doubly 
tested by secondary means to ensure against false calls. Go-
ing further, let us assume that we have: 
•  No legal (e.g. government laws) or commercial (e.g. pat-
ent restrictions and discriminatory insurance practices) 
barriers to personal genomics tests. 
•  Many examples of perfectly sequenced full diploid ge-
nomes as publicly available points of reference (e.g. 
through the Personal Genome Project (http://www.perso 
nalgenomes.org/). 
•  Increasingly detailed and comprehensive genetic data 
through public efforts such as the 1000 Genomes Project 
(http://www.1000genomes.org/). 
•  Perfect knowledge of all genetic variants in an individual 
(i.e. 100% coverage of every polymorphism in the indi- 
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•  Detailed and comprehensive assays that characterize an 
individual’s life-history, environmental health factors, 
and current health status. 
  The question posed in the remainder of this paper is – 
given the above assumptions – what computational resources 
will we need to 
•  Allow physicians and ‘patients’ to predict an individual’s 
disease susceptibilities? 
•  Evaluate the impact of life-history and life-style choices 
on these susceptibilities. 
•  Monitor potential progression towards predicted disease 
phenotypes. 
•  Recommend preventive measures (e.g. life-style changes, 
or surgery). 
•  Critique treatment alternatives (e.g. drugs vs. surgery). 
•  Learn from experience with one patient and apply the 
lesson to other cases. 
•  Keep patients’ data confidential, but allow access for 
research purposes. 
GENETIC VARIABILITY IN HUMANS 
  The prevalence of DNA sequence polymorphisms within 
the human population has been long-studied and well-
documented. Recent mapping studies [4, 5] and analysis of 
the genomic sequences of Craig Venter [6] and James Wat-
son (http://jimwatsonsequence.cshl.edu/), have confirmed 
the prevalence of both small-scale (<20bp) and large-scale 
(thousands of base pairs long) polymorphisms in individuals. 
For example, one or more of the following polymorphisms 
affect 44% of Venter’s genes: 3,213,401 SNPs, 53,823 block  
  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Gene expression variability among genetically identical 
cells. Simulated mRNA abundance distribution in 1000 genetically 
identical cells for a partially repressed gene. The histogram shows 
the distribution of mRNA molecules per cell. Super-imposed is a 
Normal distribution with the same mean and variance (continuous 
curve). The scale of the horizontal axis (mRNA abundance) is arbi-
trary. Inset: A repressor R and an activator A compete to set the 
transcriptional activity level of the gene. Both A and R protein abun- 
dances are assumed to be distributed Normally in the 1000 cells.  
substitutions (2–206 bp), 292,102 heterozygous indels (1–
571bp), 559,473 homozygous indels (1–82,711bp), and 90 
inversions [6]. 
  Traditionally, studies of DNA polymorphisms have fo-
cused on direct associations with disease (for a recent re-
view, see [7]). For example, the Online Mendelian Inheri-
tance in Man (OMIM) database (http://www.ncbi.nlm.nih. 
gov/omim/) currently lists 18,440 phenotype-associated po-
lymorphisms, while the Human Gene Mutation (HMG) data-
base (http://www.hgmd.cf.ac.uk/) currently houses over 
76,000 disease-associated genetic mutations (including small 
and large indels).  
  Recent studies suggest that many polymorphisms not 
associated with specific diseases may be responsible for sig-
nificant differences in gene expression levels between ‘nor-
mal’ ‘healthy’ individuals (see below). Indeed, it now seems 
likely that evolutionary forces such as Balancing Selection 
[8,9] are maintaining a diversity of gene expression levels 
among individuals. One implication of these findings is that 
healthy individuals may respond differently to the same 
genotype depending on their genomic background. Another 
implication is that different individuals may respond to the 
same drug very differently. Below, we explore these issues 
further. 
GENE EXPRESSION VARIABILITY AMONG INDI-
VIDUALS 
  Gene expression variation in humans is known to arise 
from at least three different mechanisms. First, non-genetic 
factors such as age, gender, and health history are well 
known to affect gene expression. Metabolic status [10], 
smoking [11], exercise [12], and emotional state [13] have 
also been shown to modulate the expression of large num-
bers of genes by 2-fold or more. For example, regular exer-
cise has been shown to lead to increased levels of the im-
mune system related cytokine IL-6 in muscle cells and also 
in the blood [14]. Such effects clearly have health implica-
tions. 
  Second, inherent transcriptional noise in individual cells 
arises from random variations in cellular content, and the 
fact that transcription is a sequential process involving a 
small number of copies of each gene [15]. Measurements in 
single mammalian cells suggest a protein abundance coeffi-
cient-of-variation of 15-30%, and long-lasting (>24 hours) 
concentration changes [16]. Thus, the abundance of the same 
protein in two genetically identical cells at steady state may 
be two to four fold different (mean+/-2SD) purely due to 
gene expression noise.  
 Fig.  (1) shows simulated mRNA abundance distribution 
in 1000 genetically identical cells for a partially repressed 
gene. The regulatory scenario is depicted in the inset. A re-
pressor R and an activator A compete to set the transcrip-
tional activity level of the gene. Both A and R protein abun-
dances are assumed to be distributed Normally in the 1000 
cells. The fractional promoter occupancy of the gene is 
therefore modeled as:  
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where square brackets denote concentrations, and K’s repre-
sent the respective protein-DNA binding association con-
stants. When [R]>0 and occupancy>0, the occupancy of the 
gene will be approximately the ratio of two Normal distribu-
tions, and therefore long-tailed. This characteristic is clearly 
visible in Fig. (1). Compare the histogram distribution of 
mRNA molecules per cell to the super-imposed Normal dis-
tribution with the same mean and variance (continuous curve). 
  Such long tails in gene expression levels have been 
widely observed (e.g. [17]). But their effect on susceptibility 
to disease and response to treatment is not yet clear. There is 
some evidence that some genetic regulatory networks em-
ploy feedback loops to reduce the degree of gene expression 
heterogeneity among cells [18]. At present, it is not clear 
how wide-spread such noise control mechanisms may be. 
  Overall, the above two mechanisms can each cause in the 
order of 2-fold expression-level differences between two 
genetically identical individuals. The third and largest cause 
of gene expression variability is DNA sequence polymor-
phisms. Polymorphisms within and across populations have 
been widely reported to cause many-fold differences in gene 
expression among individuals [19-21]. Remarkably, varia-
tions within racial groups appear to be of the same order of 
magnitude as variations between the averages for different 
racial groups. While expression differences as high as 200-
fold have been reported for specific genes [20], the average 
variability appears to be in the order of 10-fold. This level of 
variation is observed in multiple cell types and for a large 
proportion of genes in both healthy and diseased individuals 
[21]. Genes involved in the immune system – a target of 
many drugs – appear to be particularly variable, both within 
and among populations [22].  
  At present, it is not clear whether the above three sources 
of gene expression variability are additive in effect. But even 
if they are not, it appears that for a majority of genes, gene 
expression differences of ten fold or more may be common 
between any pair of individuals. 
THE NEED FOR PERSONALIZED MEDICINE 
  The effect of sequence polymorphisms on drug uptake 
and clearance rates has been well-studied over the past dec-
ade (see for example [23]). Polymorphisms in certain genes 
such as the Cytochrome P450 family can lead to consider-
able variation in drug dose response. For example, the dos-
age requirement for the anti-coagulant drug warfarin can 
vary by as much as 20-fold depending on polymorphisms in 
at least 24 DNA loci [24].  
  Given that gene expression variability among individuals 
is widespread and large in magnitude (see preceding sec-
tion), there will be significant differences in the way indi-
viduals respond to specific disease-associated mutations, 
environmental health insults (e.g. pathogens, toxic sub-
stances), and treatment regimes. For example, protective 
mutations against health threats as different as the HIV virus 
[25] and tobacco addiction [26] are well documented.  
  It is therefore increasingly clear that effective diagnosis 
(identification of danger signs), prognosis (forecast of dis-
ease progression), and treatment plans (selection of an ap-
propriate course among multiple alternatives) must be tai-
lored to the specific genetic and health-profile of each indi-
vidual patient. 
THE NEED FOR PREDICTIVE (NETWORK) MOD-
ELING OF PERSONAL DATA 
  The recent sequencing and analysis of Craig Venter’s full 
diploid genome [6] has revealed a surprisingly large number 
of multiple ploymorphisms affecting shared pathways in a 
single person. For example, Venter’s genome includes mul-
tiple genotypes associated with the increased likelihood of 
tobacco addiction. However, an additional polymorphism 
provides protection against tobacco addiction. 
  Another example of potentially complex interactions 
among multiple allelic variants arises from Venter’s geno-
types for susceptibility to Alzheimer’s Disease (AD). Dis-
ease-associated alleles for sorl1 and apoE are reported. Fig. 
(2) shows the KEGG (http://www.genome.jp/kegg/) pathway 
diagram for AD. Note the close interaction of the reported 
polymorphisms with the Amyloid Precursor Protein (APP). 
A third molecule, lipoprotein lipase (LPL) also has a com-
mon AD-associated polymorphism and interacts closely with 
the preceding three molecules.  
  To predict the subject’s susceptibility to AD, we will 
need to understand the outcome of these and other nonlinear 
interactions within the context of other variabilities within 
the genome and the life/health history of this particular indi-
vidual. Predictive modeling for individual patients is a far 
more challenging concept than anything currently attempted. 
THE NEED FOR PARTICIPATORY MEDICINE 
  As the complexity of diagnoses and treatment options 
increases, physicians are increasingly put in the difficult po-
sition of (A) having to explain the data and their implications 
to patients, and (B) having to make recommendations on the 
basis of probabilistic predictions. One way to address these 
issues is to empower participatory medicine, i.e. encourage 
patients to take an active role in healthcare planning, and 
making informed choices about preventive medicine.  
  Given that the data and their interpretation is so complex, 
how can we equip the public with intuitive analysis and 
visualization tools that allow them to understand the inter-
pretations of their data, explore prognostic models, and com-
pare treatment alternatives? Current patient-oriented educa-
tional and analytic resources such as internet searches [27], 
blogs (e.g. http://mydaughtersdna.org/) and simple risk as-
sessment calculators (see for example, http://www.framing 
hamheartstudy.org/risk/hrdcoronary.html) will be woefully 
inadequate in the era of personal genomes.  
  A complicating factor with respect to the patient-physi- 
cian relationship is known as the Expert Services Problem 
[28]. Diagnosis is becoming increasingly costly and com-
plex, and there are often multiple treatment options with dif-
fering trade-offs. As there is little comparability among pa-
tients, health service customers cannot ‘compare notes’. 
Moreover, diagnosis and treatment are usually performed by 
the same health care provider (who may be subject to finan-
cial incentives and advertising ‘spin’ from the pharma and 
biotech industries). Thus, post-hoc realization of non-optimal 
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  In short, patients increasingly find it difficult to judge the 
quality and impartiality of the diagnosis and treatment rec-
ommendations they receive. This leads to a moral hazard: 
health providers can profit from ‘over-treating’. This is 
clearly an undesirable situation. In the long term, both pa-
tients and health providers will suffer if healthcare providers 
feel there is little reward for better quality of work. These 
concerns can also be alleviated through empowering patients 
to understand their health status and prognosis better. 
THE NEED FOR INFORMATION AGGREGATORS 
AND FILTERS 
 Fig.  (3) shows the number of research papers published 
on six common diseases over the period January 2000 – 
January 2007. Even for ‘less studied’ diseases such as Os-
teoarthritis and Malaria, the number of papers published per 
day exceeds the reading time available to any individual. 
Moreover, relatively few individuals will have the technical 
knowledge to understand the subject matter and judge the 
implications of the findings appropriately.  
  In response to the above information glut, much recent 
research has focused on developing information aggregators. 
For example, the pathway resources directory PathGuide 
(http://www.pathguide.org/) currently lists 240 databases of 
biological pathways. It is very useful to have a central direc-
tory of all available pathway databases. But it is unlikely that 
anyone will have the time and expertise to retrieve relevant 
content from all 240 available databases, judge their rele-
vance, and extract useful conclusions.  
  There is clearly a need for computational approaches that 
summarize relevant and trustworthy data from the very large 
amount of information available in publications and data-
bases, and make them available to researchers, practicing 
physicians, and proactive patients in easily digestible forms. 
COMPUTATIONAL SUPPORT FOR PERSONAL GE-
NOMICS AND PERSONAL MEDICINE 
  The preceding sections focused on describing some of 
the computational challenges posed by personal genomics. 
The purpose of this section is to suggest some possible solu-
tions. In particular, I propose that existing internet-based 
technologies can be adapted to meet most of the challenges 
envisaged.  
  Consider the following example “use case scenarios”: 
(1) An individual has had multiple genomic, proteomic and 
other analysis performed, and now needs to understand 
the implications of the results. Should she have an opera-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Common polymorphisms in the genes associated with Alzheimer’s Disease (AD). The pathway diagram is from KEGG 
(http://www.genome.jp/kegg/). Three common mutations (SORL1, LRP, APOE) interact with each other and with APP. The outcome of 
such interactions in the genomic background of a single individual is difficult to predict. 84    Current Genomics, 2008, Vol. 9, No. 2  Hamid Bolouri 
tion (potentially debilitating, or dangerous); should she 
take a drug (with inevitable side-effects); or should she 
make (potentially difficult or costly) "pre-emptive" life-
style changes? 
(2) A physician has received the above person's data and is 
considering the same questions. The physician requires 
greater technical details and more quantitative data (e.g. 
serum test data, drug dose-response/interaction data, etc), 
and additional information on legal and contractual con-
straints (e.g. FDA regulations, and patient insurance 
terms), but she may not have extensive training in genet-
ics, and will not have time to read the vast majority of the 
research literature relevant to the patient’s data. 
(3) A research scientist is working on a disease to which the 
above patient/client appears to be susceptible. The re-
searcher can pay far greater attention to detail than either 
the ‘patient’ or the physician. She will also be willing and 
able to use much more sophisticated data analysis tools, 
and may well spend many years investigating the same 
topic and building up personal familiarity with the sub-
ject.  
  The patient, doctor and researcher all need to understand 
the same pool of available data, and share many challenges 
(data overload, too many tools to learn, complex theory un-
derlying analysis methods, etc.). The conjunction of the in-
terests of these three large user-communities provides a very 
large potential market, and makes the development of a 
computational infrastructure for personal genomics an attrac-
tive investment.  
Semantic Ontologies for Personal Genomics 
  The development of a semantic ontology (the association 
of meaning with data) for personal genomics and health in-
formatics would be a crucial first step to the development of 
computational resources for personal genomics. 
  While the development of a general-purpose ‘semantic 
web’ may be too difficult to yield fruit in the near future, 
ontologies for well-defined scientific domains such as medi-
cal informatics and genomics are much easier to define un-
ambiguously. Indeed, efforts to develop a semantic ontology 
for medical informatics are well underway (http://esw.w3. 
org/topic/SemanticWebForLifeSciences). Similar efforts are 
needed for personal genomics. In particular, personal genom-
ics will need to build a semantic bridge between the medical 
community, and the molecular systems biology community, 
which also has a number of emerging ontology standards 
(e.g. http://www.geneontology.org/, http://sbml.org/, http:// 
www.cellml.org/, http://www.biopax.org/).  
  The establishment of a common semantic ontology for 
personal genomics and medicine would permit two impor-
tant developments. First, it allows software tools to interpret 
genetic, genomic, pharmacological, and medical data. This in 
turn will allow the development of sophisticated computa-
tional tools that adapt their resources and output to the needs 
and expertise of their users.  
  Second, and at least as important, semantically tagged 
personal genomic, pharmacological, and medical data permit 
‘bottom-up’ (or community-based) participation in the ana- 
lysis of public data. Semantically-tagged data can be compu-
tationally filtered, categorized, and summarized. As a result, 
users who are not experts in computer science, biology, or 
medicine can use web-services to search large numbers of 
semantically-tagged databases, and collate their own dossiers 
of relevant, up-to-date information. 
  Community-based internet resources such as customer 
ratings, reviews, and wikis have already had a major impact 
in many domains of life. They are characterized by their par-
ticipatory and highly fluid content, and benefit from ‘wis-
dom of the crowds’ effects. These characteristics stand in 
direct contrast to existing ‘top-down’ (or authoritative) in-
formation resources (e.g. FDA databases), which typically 
enforce objectivity and hierarchical quality assurance at the 
expense of adaptability and rapid response.  
  In recent years, both medical informatics systems and 
computational molecular systems biology have come of age. 
As discussed below, there are already a broad range of com-
putational resources that could be adapted for use in personal 
genomics and personalized medicine settings. 
 
 
 
 
 
 
 
 
Fig. (3). Average number of papers published per day for some common diseases. The numbers given on the right hand side of the fig-
ure are the 2006 averages. The numbers were collected from the Web of Science (http://scientific.thomson.com/products/wos/) for the period 
1
st January 2000 to 1
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Medical Informatics Frameworks 
  In medical informatics, there are already a number of 
excellent medical information management systems. Two 
good examples are the award-winning VISTA system devel-
oped by the Veteran’s Association of USA (http://www. 
virec.research.va.gov/DataSourcesName/VISTA/VISTA.htm) 
and the clinical health services framework implemented by 
the Boston-based CareGroup [29]. The latter currently serves 
over 3000 MDs, handles some 250 Terra Bytes of data per 
day, and employs some 250 IT staff. Thus, by any measure, 
there is track-record and willingness in the medical sector for 
the introduction of strong computational support.  
  At present, the above medical informatics resources fo-
cus on providing automated patient records and transaction 
support (e.g. physician-physician consultations, ordering 
drugs, setting up treatment plans, etc). However, efforts are 
also under way to allow these frameworks to provide some 
decision support. For example, the system implemented by 
CareGroup alerts physicians if the patient is known to have 
an allergy to a drug they have prescribed. Thus, decision-
support based on more detailed patient data would be a natu-
ral further development in medical informatics. 
Computational Systems Biology 
  In the area of molecular systems biology too, many use-
ful tools have been developed for data visualization, analysis 
and modeling. These include tools for integrative network 
modeling (e.g. http://cytoscape.org/ and http://www.biotape 
stry.org/), tools for exploring genome-scale associations (e.g. 
http://www.caida.org/tools/visualization/walrus/), tools for 
concurrent, multiple transformations and visualizations of 
high-dimensional data (e.g. http://www.ggobi.org), selective-
focus comparisons of hierarchical categorical data (http:// 
olduvai.sourceforge.net/), and many more. My purpose in 
listing the preceding examples is to emphasize the breadth of 
tools available and their relative maturity. 
  At present, there is no coupling between the above mo-
lecular biology research tools and the clinical IT environ-
ments described earlier. Any information flow between the 
two domains is currently ad-hoc and primarily through indi-
viduals with interests in both domains. With the advent of 
personal genomics it is increasingly imperative that we inte-
grate basic research, medical practice, and patient-centered 
services.  
 Fig.  (4) provides a schematic summary of such integra-
tion. Currently, data flow from research to practice occurs 
over years. In the proposed scheme, the computational infra-
structure for these two communities is shared. One advan-
tage of such sharing is that the tools that the patient, physi-
cian, and research communities use can essentially be differ-
ent user-interfaces to the same underlying computational 
engines. Another advantage is that results from specific 
medical tests can be analyzed in the context of global 
datasets. The gray arrow going back from medicine to mo-
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Proposed integration of molecular systems biology computational tools with medical informatics decision-support tools. The 
cartoon funnels represent information-theoretic frameworks for aggregation, filtering and summary-reporting of local test results with gen-
eral background knowledge mined from the literature and 3
rd party databases. IT stands for Information Technology. As described in the text, 
all data processing is assumed to be performed through security-certified web services. All data will reside with the patient and be available 
only for patient-authorized appropriately anonymized analysis tasks. In this way, the scheme provides a mechanism for data security while 
also allowing researchers to analyze and learn from patient data. Although not shown explicitly in the figure, the proposed integration will 
also facilitate understanding of personal data by patients through enabling a large variety of software tools to explore the same data using a 
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lecular biology research indicates that the proposed infra-
structure will also permit researchers to explore clinical data. 
Such access can be mediated through security-certified web 
services, as outlined below.  
Data Privacy and Security 
  Given that complex data analysis will need to be per-
formed in order to interpret the health implications of DNA 
polymorphisms, how will we ensure the privacy of patients 
and the security of the data? In spite of the removal of per-
sonal identity information from public databases, it may be 
possible to reconstruct individual identities by association of 
multiple genetic traits and medical records with personal 
profiles (e.g. health histories) of individuals.  
  Ideally, we need to ensure complete patient privacy, 
while allowing anonymized patient data to be mined for re-
search. One solution is to allow individuals to keep their own 
data, and to make informed choices as to who has access to 
the data. Researchers and medical practitioners can use web 
services and applications that do not store data locally (such 
as Java web start) to analyze data on-the-fly through pre-
defined filters. By keeping data in only one location (i.e. the 
patient’s own data vault), data security risks can be mini-
mized while maximizing data access privileges.  
CONCLUSIONS 
  Personal genomics may not be profitable yet, but it is 
already a commercial reality. The extent to which personal 
genomics and personalized medicine will benefit the public 
at large will depend on the extent to which the technological 
breakthroughs are accompanied by appropriate computa-
tional developments that allow users to participate in deter-
mining appropriate responses to diagnostic data. Moreover, 
we need to develop the appropriate computational infrastruc-
ture before the technology for personal genomics becomes 
widely available, because poorly interpreted data is likely to 
lead to misdiagnoses and a potential public backlash against 
a very promising revolution in medicine. 
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